12 results about "Dose-effect relationship" patented technology

The invention relates to the technical field of environmental monitoring and analysis detection, in particular to a soil heavy metal ecological risk microorganism rapid detection method and system.The method comprises the steps that soil sample microorganism sensor signals are collected, biotoxicity response characteristics are extracted, and a biotoxicity response spectrum data set is constructed; establishing a dose effect relation matrix according to the data set, training a support vector machine model to obtain a stability index, determining an information fusion weight, and establishing a biological signal baseline and heavy metal concentration mapping model after fusing features; acquiring signals of a to-be-detected sample, extracting features, inputting biotoxicity response features into the support vector machine model, outputting prediction confidence to correct fusion weight, obtaining to-be-detected fusion features, calculating biological signal deviation, outputting a heavy metal concentration prediction value, and determining pollution level and ecological risk level. According to the method, the result stability and the field screening availability are improved.

The invention discloses a double-antibody sandwich ELISA method for detecting the concentration of an HSC70 / STUB1 compound in serum, and belongs to the technical field of biomedical detection. The method specifically comprises the following steps: (1) coating; (2) washing; (3) sealing; (4) adding a sample; (5) adding a detection antibody; (6) developing; (7) terminating and detecting; and (8) quantitative analysis. The method disclosed by the invention can be used for carrying out high-sensitivity, high-specificity, accurate quantitative and high-throughput detection on the HSC70 / STUB1 compound in serum, and meanwhile, a reliable and convenient detection means is provided for researching a dose-effect relationship between the BP-3 environmental exposure level and the formation of the STUB1-HSC70 compound in vivo; an effective tool is provided for early diagnosis, risk prediction and mechanism research of related diseases, and the blank of the field in clinical transformation application is filled.

This invention relates to the field of environmental monitoring and analysis technology, and particularly to a rapid detection method and system for soil heavy metal ecological risk microorganisms. The method includes: collecting microbial sensor signals from soil samples and extracting biotoxicity response features to construct a biotoxicity response spectrum dataset; establishing a dose-response relationship matrix from the dataset, training a support vector machine model to obtain stability indices and determine information fusion weights, and establishing a mapping model between the biological signal baseline and heavy metal concentration after feature fusion; acquiring signals from the sample to be tested and extracting features, inputting the biotoxicity response features into the support vector machine model to output prediction confidence to correct the fusion weights, obtaining the fused features to be tested, calculating the biological signal bias, and outputting the predicted heavy metal concentration value, thereby determining the pollution level and ecological risk level. This invention improves the stability of results and the usability for on-site screening.

The invention discloses a method for evaluating the toxicity of dust affecting bacterial colony growth, which comprises the following steps: S1, preparing dust, crushing and grinding the dust, screening out dust with different particle sizes, and culturing escherichia coli in an LB culture medium; s2, preparing a liquid culture system; step S2.1, performing a dust exposure experiment; step S2.2, a dust leachate experiment is carried out; s3, preparing a solid culture system; s3.1, performing a dust exposure experiment; s3.2, a dust leaching solution experiment is carried out; s4, analyzing the physicochemical characteristics of the dust, and establishing a dose-effect relation model among the physicochemical components, the morphological characteristics, the particle size, the concentration and the bacterial colony growth toxicity effect of the dust by adopting a regression analysis method according to the data; the method has the advantages of rapidness, high efficiency, accurate data, low cost, wide application prospect and the like.

The application discloses a Zm00001eb038700 gene for regulating corn plant height and application thereof. The nucleotide sequence of the gene is shown as SEQ ID NO:1, and the expression amount of the gene is positively correlated with the corn plant height. The amino acid sequence of the protein coded by the gene is shown as SEQ ID NO:2, the protein codes a conserved C2H2 type zinc finger protein Bud20, and the protein may be involved in the development regulation of the internode part so as to affect the corn plant height. The SNP1-206,628,704 site is located at the downstream 3801bp of the gene; when the genotype of the site is CC, the corn shows a dwarf trait; and when the genotype is changed into AA, the corn shows a high-stalk dominant trait. The application firstly discloses the dose-effect relationship between the expression level of the Zm00001eb038700 gene and the corn plant height, the associated SNP can explain 3.57% of the plant height phenotype variation. The application develops a molecular marker combination combining the SNP genotype and the gene expression amount, and the prediction accuracy of the plant height is obviously improved. Therefore, the results of the application provide technical support for breeding corn varieties with suitable plant type and high yield.

The invention discloses application of 3-hydroxyglutaric acid in preparation of a medicine for preventing and / or treating hyperuricemia related diseases and the prevention and treatment medicine. The activity of 3-hydroxyglutaric acid capable of reducing the uric acid level in the body is found and confirmed for the first time, and the 3-hydroxyglutaric acid is pioneering discovery of new application of known substances; through rigorous dose effect relationship research, a'treatment window 'which is lower than a toxicity threshold value and can effectively reduce uric acid is determined. As an endogenous metabolic intermediate of a human body, the biocompatibility under low dosage is expected to be superior to that of a chemically synthesized medicine, and the potential side effect risk after long-term use is lower.

The invention relates to the technical field of pollutant treatment and environmental microorganisms, and provides a pollutant early warning method for preventing and controlling transmission of antibiotic resistance genes in a water environment. The conjugational transfer frequency of the antibiotic resistance gene is used as a quantitative core index, and after the quantitative core index and the environmental factor concentration of the pollutant are subjected to dose-effect relationship construction and analysis, a concentration range for promoting the propagation of the antibiotic resistance gene is obtained and is used as an early warning threshold value to early warn the propagation risk of the antibiotic resistance gene. According to the method, objectiveness and accuracy of threshold determination are achieved by combining the quantitative index of the transfer frequency or the conversion rate with the dose-effect relation, and subjective judgment is avoided.

The invention relates to the field of focused ultrasound, in particular to a parameter positioning method and kit for inhibiting PCOS concurrent epilepsy based on focused ultrasound. The method comprises the following steps: acquiring different power and duty ratio combinations corresponding to a plurality of preset gears; according to the prior experiment data and the biological thermal model, predicting safety intervals of stimulation duration under different gears, and setting a plurality of experiment parameter combinations of different preset doses according to the safety intervals; performing ultrasonic stimulation on the experimental model based on the experimental parameter combination to obtain a biological response result; based on a preset dose effect relationship, according to the biological response result, respectively fitting a dose effect curve under each gear; and determining an optimal dose range of each gear based on the dose effect curve, and performing feasibility evaluation on the optimal dose range to determine an optimal parameter combination of focused ultrasound. On the premise of simple experimental operation, short period and low cost, a relatively accurate and effective ultrasonic parameter range is efficiently determined, and support is provided for personalized medical treatment.

This application relates to the field of focused ultrasound, and more particularly to a parameter localization method and kit for inhibiting PCOS-related epilepsy using focused ultrasound. The method includes: acquiring multiple preset power levels, each corresponding to different combinations of power and duty cycle; predicting the safe range of stimulation duration at different power levels based on prior experimental data and a biothermal model; setting several experimental parameter combinations with different preset doses based on the safe ranges; performing ultrasound stimulation on an experimental model based on the experimental parameter combinations and obtaining biological response results; fitting dose-response curves for each power level based on a preset dose-response relationship and the biological response results; determining the optimal dose range for each power level based on the dose-response curves, and evaluating the feasibility of the optimal dose range to determine the optimal parameter combination for focused ultrasound. This method efficiently determines a relatively accurate and effective range of ultrasound parameters while maintaining simple experimental operation, short cycle time, and low cost, providing support for personalized medicine.

The invention discloses an exosome miRNAs biomarker for evaluating the radiation exposure dose of a human body and application of the exosome miRNAs biomarker, the radiation exposure dose is calculated according to the dose effect relationship between the expression quantity of the exosome miRNAs and the radiation exposure dose, and the exosome miRNAs comprise miR-664b-3p, miR-551b-3p, miR-181b-5p, miR-125b-5p, miR-27a-3p, miR-18a-5p, miR-29a-3p and let-7i-5p. The method has the advantages of being convenient and minimally invasive in sampling, easy and convenient to operate and high in flux, the problems that in the prior art, the process is tedious, and consumed time is long can be solved, and the requirement for dose evaluation on large-scale crowds in nuclear and radiation emergencies is met.

The application provides an application of an immune response biomarker in prognosis evaluation of a liver cirrhosis patient treated by mesenchymal stromal cells, relates to the field of biological medical technology, and the immune response biomarker comprises MX1 positive mononuclear cells or / and LGALS2 positive mononuclear cells, potential biomarkers LGALS2 positive mononuclear cells and MX1 positive mononuclear cells for predicting the dose-effect relationship of MSC treatment are screened, the proportion of MX1 positive mononuclear cells at a baseline of the liver cirrhosis patient is significantly increased (P<0.01) compared with a healthy control, and the proportion of LGALS2 positive mononuclear cells is significantly reduced (P<0.05); the change trend of the biomarker under the MSC dose and the regulation effect on other immune cell subgroups are identified through sequencing analysis, the dose-effect relationship of the immune regulation mediated by MSC can be accurately reflected, and patients with a low recurrence risk in MSC treatment prognosis are identified.

The application discloses application of 3-hydroxyglutaric acid in preparation of a medicine for preventing and / or treating a high uric acid related disease and a preventive and therapeutic medicine. The application firstly discovers and proves that 3-hydroxyglutaric acid has the activity of reducing the uric acid level in vivo, is a pioneering discovery of new use of known substances, and determines a "treatment window" which is lower than a toxicity threshold and can effectively reduce uric acid through a rigorous dose-effect relationship study. As a metabolic intermediate in vivo, the biological compatibility of 3-hydroxyglutaric acid at a low dose is expected to be better than that of a chemically synthesized medicine, and the potential side effect risk of long-term use is lower.